Summary
This seminar covers a broader spectrum of utility breath analysis by shortlisting and discussing interventions that can be used to assess and determine the existence of various diseases. The speaker’s point is mainly anchored on the manifestation of Nitric Oxide in the breadth, and how it invokes different medical implications in the breath. In a nutshell, this speech conclusively discusses how breath examination and analysis leads to the determination or realization of diseases such as Asthma, Pulmonary Hypertension, Heart Disease, Lung Cancer, and other diseases.
The concept of breath analysis serves in the interest of medical diagnosis to the most diseases that are inherent to the body, and these means vary from simple to complex procedures of diagnosing the disease. However, the level of n Nitric Oxide in the breath is indicative of a particular illness, though it might imply the presence of multiple diseases.
Moreover, the core discussion is leveled against the exhaled Nitric Oxide and how it determines the level of Asthma in a patient. In most medical diagnostic interventions, the concentration level of FENO has been used a basis for measuring the existence of asthma in an individual, as well as the intensity of the diseases. Right from the earlier measures of breath analysis to the latest model, a lot of conformity has been lauded to Nitric Oxide exhalation to the level of Asthma. More commonly, the respiratory system has been relied upon as a system for identifying various diseases.
Much to the Asthma diagnostic tests, the rate of breathing might influence the detected level of this disease in a patient; this requires deeper and due consideration of all parameters that affects breathing. In summary, FENO is used in Asthma tests for diagnosis, monitoring the level of disease, titration, and evaluation breath.
Moreover, this seminar talked a great deal about some utility tests for breath against other diseases by invoking special equipment. The use of CXR, CT images, an algorithmic test to test the level of lung cancer. Other methods influence the use of wild systems, and the electronic nose to test exhaled air for diseases such as lung cancer. Besides, the use of mass spectrometry has been upheld in this seminar as a means of testing ion concentration in the breath and determining the concentration levels of diseases like pulmonary hypertension, liver diseases, among others (Groß, 2010). This is a brief narrative of what transpires in the online text, notwithstanding that challenges about these tests are elucidated at the end.
Questions
1. What are the implications of carrying tests to detect a systematic disease on an individual?
2. How has technology in medicine advanced reliability and efficiency of medical tests to systematic disease?
These questions are meaningful to the seminar, and at least reverberate on the test interventions that apply to the breath analysis. The unfolding talk has focused on the breath analysis and key diagnostic interventions, while invoking the essence of technology and how they apply to the pulmonary disease. The electronic nose is a test method that is used to test the presence of lung cancer, and in the same place, tests like mass spectrometry could be used to diagnose this disease (Horvath, Jongste, & European Respiratory Society, 2010). Therefore, these tests have varied manifestation, where mass spectroscopy intervenes by measuring the level of the ion to determine the concentration of either liver disease or lung cancer (De, & Stroobant, 2013). Thus, the function of invoking several tests is to enhance the reliability of the outcome than relying on one test that might be misleading (Bayless, & Diehl, 2005). For example, the level of concentration of ion signifies the intensity of pulmonary disease that a person has.
The use of technology has significantly accelerated the reliability and efficiency of medical tests. From a simple breathalyzer test to a sophisticated mass spectrometry tests, technology is the hallmark of its progress (In Biller, & In Ferro, 2014). Today, tests have become so sophisticated and can identify finer details of diseases, which are beyond the obvious clinical interventions. Thus, the use of advanced technological, medical interventions to diagnose pulmonary diseases leads to the realization of more precise results compared to conventional methods of testing. For example, the use of mass spectrometry leads detects the liver disease, and level of ion concentration, while electronic nose has the capability of detecting the disease, but cannot specify details of the disease.
References
Bayless, T. M., & Diehl, A. (2005). Advanced therapy in gastroenterology and liver disease. Hamilton, Ont: B. C. Decker.
De, H. E., & Stroobant, V. (2013). Mass Spectrometry: Principles and Applications. New York, NY: John Wiley & Sons.
Groß, J. (2010). Mass Spectrometry: A Textbook. Berlin: Springer Berlin.
Horvath, I., Jongste, J. C., & European Respiratory Society. (2010). Exhaled biomarkers. Sheffield: European Respiratory Society.
In Biller, J., & In Ferro, J. M. (2014). Neurologic aspects of systemic disease.
